Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2022 Jun 28:2022:9619699.
doi: 10.1155/2022/9619699. eCollection 2022.

Characteristics of Pharmacists' Interventions Related to Proton-Pump Inhibitors in French Hospitals: An Observational Study

Affiliations
Observational Study

Characteristics of Pharmacists' Interventions Related to Proton-Pump Inhibitors in French Hospitals: An Observational Study

A L Yailian et al. Int J Clin Pract. .

Abstract

Methods: The study was based on a retrospective analysis of pharmacist interventions for DRPs detected during the medication order review and documented into the French Act-IP© database over a 12-year period. DRPs and PIs were analyzed, and independent factors of physician acceptance were assessed via multiple logistic regression.

Results: Out of the 620,620 PIs registered, 29,694 targeted a PPI (4.8%). PPI's DRPs were mostly related to the prescription of a "drug not available at the hospital" (26.1%) and a "drug use without indication" (18.3%); PIs were mostly "drug switch" (35.9%) and "drug discontinuation" (26.1%). In all, 18,919 PIs were accepted by physicians (63.7%). Acceptance was significantly associated with patient age: less accepted for the 18-75 years group (OR = 0.59, 95 CI [0.46-0.76]), and the >75 years group (OR = 0.57, 95 CI [0.44-0.73]) vs. <18 years group; for the type of DRP, "drug use without indication" was the less accepted (OR = 0.73, 95 CI [0.63-0.85]); for the type of PI, "dose adjustment" was the less accepted (OR = 0.32, 95 CI [0.23-0.45]).

Conclusion: Pharmacists contribute to preventing DRPs associated with PPI prescriptions during the medication order review process. Moreover, they often detect PPIs used without indication and they propose drug discontinuation, which contributes to the PPI deprescribing process. PIs should be further developed in the future to reduce PPI overprescription.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

References

    1. Savarino V., Dulbecco P., de Bortoli N., Ottonello A., Savarino E. The appropriate use of proton pump inhibitors (PPIs): need for a reappraisal. European Journal of Internal Medicine . 2017;37:19–24. doi: 10.1016/j.ejim.2016.10.007. - DOI - PubMed
    1. Forgacs I., Loganayagam A. Overprescribing proton pump inhibitors. BMJ . 2008;336(7634):2–3. doi: 10.1136/bmj.39406.449456.be. - DOI - PMC - PubMed
    1. Bourne C., Charpiat B., Charhon N., et al. Effets indésirables émergents des inhibiteurs de la pompe à protons. La Presse Médicale . 2013;42(2):e53–e62. doi: 10.1016/j.lpm.2012.09.016. - DOI - PubMed
    1. Scarpignato C., Gatta L., Gatta A., Zullo A., Blandizzi C. Effective and safe proton pump inhibitor therapy in acid-related diseases - a position paper addressing benefits and potential harms of acid suppression. BMC Medicine . 2016;14(1):p. 179. doi: 10.1186/s12916-016-0718-z. - DOI - PMC - PubMed
    1. Salvo E. M., Ferko N. C., Cash S. B., Gonzalez A., Kahrilas P. J. Umbrella review of 42 systematic reviews with meta‐analyses: the safety of proton pump inhibitors. Alimentary Pharmacology & Therapeutics . 2021;54(2):129–143. doi: 10.1111/apt.16407. - DOI - PubMed

Publication types

Substances